Patrick Most

Title: The Innovative Contributions of Patrick Most

Introduction

Patrick Most is a notable inventor based in Philadelphia, PA, who has made significant strides in the field of gene therapy and cardiac treatment. With a total of 2 patents, his work focuses on addressing critical health issues such as heart failure and vascular dysfunction.

Latest Patents

Among his latest patents, the first is a tissue-specific gene therapy treatment. This invention provides nucleic acid segments, compositions, and methods for treating heart failure, vascular dysfunction, endothelial dysfunction, diabetes, calcium ion regulation, and nitric oxide synthase dysfunction. The use of adeno-associated and adenovirus as gene delivery vectors allows for the long-term over-expression of S100A1, a small calcium-sensing protein associated with these ailments. The second patent relates to the treatment of cardiac power failure. This invention involves medicaments that contain a therapeutically effective quantity of one or more S100 proteins or their mutants or fragments. Additionally, it may include nucleic acid sequences coding for these proteins, which can be integrated into gene transfer vectors.

Career Highlights

Patrick Most has worked at Thomas Jefferson University, where he has contributed to advancing medical research and innovation. His work has been instrumental in developing therapies that target complex health issues.

Collaborations

Throughout his career, Patrick has collaborated with esteemed colleagues such as Hugo A. Katus and Andrew Remppis, further enhancing the impact of his research and inventions.

Conclusion

Patrick Most's innovative contributions to gene therapy and cardiac treatment highlight his dedication to improving health outcomes. His patents reflect a commitment to addressing significant medical challenges through scientific advancement.